surmount-1 tirzepatide trial obesity without diabetes on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 A 3-year study of tirzepatide
Description
At 1-2 pounds per week (a safe, sustainable rate), expect 10-20 weeks
15 mg-2 group: 35.7%
The results will last as long as you continue to receive your weekly injections
Tirzepatide, a novel medication gaining attention for its dual action on blood sugar and body weight, represents a significant breakthrough in the realm of obesity care
Our programs have been designed by leading nutritionists and have been tried and tested for decades
